Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

Dementia with Lewy bodies (DLB) and Parkinson's Disease (PD) are common causes of motor and cognitive deficits and are associated with the abnormal accumulation of alpha-synuclein (α-syn). This study investigated whether passive immunization with a novel monoclonal α-syn antibody (9E4) against the C-terminus (CT) of α-syn was able to cross into the CNS and ameliorate the deficits associated with α-syn accumulation. In this study we demonstrate that 9E4 was effective at reducing behavioral deficits in the water maze, moreover, immunization with 9E4 reduced the accumulation of calpain-cleaved α-syn in axons and synapses and the associated neurodegenerative deficits. In vivo studies demonstrated that 9E4 traffics into the CNS, binds to cells that display α-syn accumulation and promotes α-syn clearance via the lysosomal pathway. These results suggest that passive immunization with monoclonal antibodies against the CT of α-syn may be of therapeutic relevance in patients with PD and DLB.

[1]  Beate Ritz,et al.  Replication of GWAS Associations for GAK and MAPT in Parkinson's Disease , 2010, Annals of human genetics.

[2]  Eden R Martin,et al.  Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.

[3]  D. Galasko,et al.  Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy , 2010, PloS one.

[4]  E. Masliah,et al.  Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies , 2010, Experimental Neurology.

[5]  R. Benz,et al.  Structural properties of pore-forming oligomers of alpha-synuclein. , 2009, Journal of the American Chemical Society.

[6]  E. Masliah,et al.  Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases , 2009, The Journal of Neuroscience.

[7]  E. Sigurdsson.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. , 2009, Current Alzheimer research.

[8]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[9]  V. Subramaniam,et al.  Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. , 2009, Biochimica et biophysica acta.

[10]  E. Masliah,et al.  Role of Synucleins in Alzheimer’s Disease , 2009, Neurotoxicity Research.

[11]  David Park,et al.  Abberant α-Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy , 2009, PloS one.

[12]  T. Tokuda,et al.  CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease , 2009, Brain Research.

[13]  E. Masliah,et al.  Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[14]  V. Subramaniam,et al.  Membrane binding of oligomeric α‐synuclein depends on bilayer charge and packing , 2008, FEBS letters.

[15]  E. Masliah,et al.  Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases , 2008, PloS one.

[16]  M. Xilouri,et al.  Alpha-synuclein degradation by autophagic pathways: A potential key to Parkinson’s Disease pathogenesis , 2008, Autophagy.

[17]  He-Jin Lee,et al.  Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. , 2008, Biochemical and biophysical research communications.

[18]  Brian Spencer,et al.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.

[19]  E. Masliah,et al.  Transgenic animal models of neurodegenerative diseases and their application to treatment development. , 2007, Advanced drug delivery reviews.

[20]  D. Mann,et al.  An investigation into the lipid-binding properties of α-, β- and γ-synucleins in human brain and cerebrospinal fluid , 2007, Brain Research.

[21]  Julia Thom Oxford,et al.  Calpain-Cleavage of α-Synuclein : Connecting Proteolytic Processing to Disease-Linked Aggregation , 2007 .

[22]  E. Masliah,et al.  Dynamics of α‐synuclein aggregation and inhibition of pore‐like oligomer development by β‐synuclein , 2007 .

[23]  Michael L. Kramer,et al.  Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies , 2007, The Journal of Neuroscience.

[24]  V. Uversky,et al.  Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail. , 2006, Biochemistry.

[25]  M. Sadowski,et al.  Clearance and prevention of prion infection in cell culture by anti‐PrP antibodies , 2006, The European journal of neuroscience.

[26]  C. Lemere,et al.  Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. , 2006, Rejuvenation research.

[27]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[28]  E. Masliah,et al.  β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[29]  J. Marsh,et al.  Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Smita Patel,et al.  Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.

[31]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[32]  Olga Pletnikova,et al.  Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Sierks,et al.  A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein , 2004 .

[34]  V. Subramaniam,et al.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. , 2004, Biochemistry.

[35]  Manuel Buttini,et al.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. , 2004, The American journal of pathology.

[36]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[37]  H. Gendelman,et al.  Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Bin Yuan,et al.  Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments† , 2004 .

[39]  E. Masliah,et al.  α‐Synuclein up‐regulates expression of caveolin‐1 and down‐regulates extracellular signal‐regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease , 2003 .

[40]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[41]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[42]  M. Mallory,et al.  Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42 , 2001, Journal of neuroscience research.

[43]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.

[45]  E. Masliah,et al.  Reduced Neuritic Outgrowth and Cell Adhesion in Neuronal Cells Transfected with Human α-Synuclein , 2001, Molecular and Cellular Neuroscience.

[46]  I. McKeith,et al.  Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. , 2000, Neurologic clinics.

[47]  M. Tabaton,et al.  Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects , 2000, Neuroscience Letters.

[48]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[49]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[50]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[51]  P. Lansbury.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[53]  E. Masliah,et al.  Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[54]  J. Trojanowski,et al.  Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. , 1998, Archives of neurology.

[55]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[56]  J. Trojanowski,et al.  Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains a , 1996, Annals of the New York Academy of Sciences.

[57]  J. Trojanowski,et al.  Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. , 1996, The American journal of pathology.

[58]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[59]  E. Sigurdsson.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. , 2008, Journal of Alzheimer's disease : JAD.

[60]  Seung-Jae Lee.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. , 2008, Journal of molecular neuroscience : MN.

[61]  He-Jin Lee,et al.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. , 2008, The international journal of biochemistry & cell biology.

[62]  Michael L. Kramer,et al.  Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[63]  E. Masliah,et al.  Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. , 2007, The FEBS journal.

[64]  D. Mann,et al.  An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid. , 2007, Brain research.

[65]  E. Masliah,et al.  Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. , 2007, The American journal of pathology.

[66]  Seung-Jae Lee.  Origins and Effects of Extracellular α-synuclein: Implications in Parkinson’s Disease , 2007, Journal of Molecular Neuroscience.

[67]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[68]  R. Edwards,et al.  Neural activity controls the synaptic accumulation of alpha-synuclein. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[69]  R. Black,et al.  A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. , 2005, Neuro-degenerative diseases.

[70]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[71]  Y. Lyubchenko,et al.  Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. , 2004, Biochemistry.

[72]  M. Sierks,et al.  A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  E. Masliah,et al.  Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. , 2003, Journal of neurochemistry.

[74]  M. Tabaton,et al.  Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. , 2000, Neuroscience letters.

[75]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. , 1999, Neuroreport.

[76]  J. Tildon,et al.  Utilization of ketone bodies and glucose by established neural cell lines , 1982, Journal of neuroscience research.